Related Experiment Video
Updated: Sep 10, 2025

Visualization of HIV-1 Gag Binding to Giant Unilamellar Vesicle GUV Membranes
Published on: July 28, 2016
Negative interplay between HIV-1 Gag and amyloid precursor protein centers around competition for VPS4A and TSG101
1Department of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611.
Abstract:
Intracellular multivesicular bodies (MVBs) act as sites of assembly and release of HIV type 1 (HIV-1) in macrophages and microglia. Recent work has shown that processing of amyloid precursor protein (APP) into a C-terminal fragment (CTF), termed C99, inhibits HIV-1 access to CD63+ MVBs and to counteract this, HIV-1 Group-specific antigen (Gag) increases C99 processing into toxic amyloids. However, the underlying reasons for this negative interplay between Gag and C99 remain unclear. Here, we show that HIV-1 Gag polyprotein and APP processing pathways intersect and compete, relying in different ways on two vesicular trafficking components: the endosomal sorting complexes required for transport protein, TSG101, and vacuolar protein sorting (VPS) subunit, VPS4A. VPS4A plays a complex role in infection by both directly regulating virion production and the abundance of distinct CTFs with differing subcellular localizations and effects on infection. Meanwhile, APP and C99's use of TSG101 for insertion into vesicles limits Gag access to MVBs. Depletion of TSG101 resulted in impaired Gag localization to MVBs and processing into mature virions, and this could be partially reversed by codepletion of APP. By contrast, modulation of TSG101 or APP levels had no effect on the localization patterns of a Gag-P6 mutant that is unable to bind TSG101, while this mutant also failed to promote C99 degradation. Our findings reveal how CTF processing and HIV-1 maturation at MVBs converge in complex ways around VPS4A and TSG101, which in turn underlies how these processes negatively influence one another during virus replication in microglia.
Insights
HIV-1 Gag and amyloid precursor protein (APP) processing pathways intersect, competing for vesicular trafficking proteins TSG101 and VPS4A. This competition impacts HIV-1 replication in microglia.
Area of Science:
- Virology
- Cell Biology
- Neuroscience
Background:
- Intracellular multivesicular bodies (MVBs) are critical for HIV-1 assembly and release in macrophages and microglia.
- Amyloid precursor protein (APP) processing into C99 fragment inhibits HIV-1 entry into CD63+ MVBs, prompting HIV-1 Gag to enhance C99 processing into toxic amyloids.
Purpose of the Study:
- To elucidate the molecular mechanisms underlying the negative interplay between HIV-1 Gag and APP processing pathways.
- To investigate the roles of TSG101 and VPS4A in HIV-1 maturation and APP metabolism.
Main Methods:
- Investigated the interaction between HIV-1 Gag polyprotein and APP processing pathways using depletion and codepletion strategies.
- Utilized a Gag-P6 mutant to assess the role of TSG101 binding in Gag localization and C99 degradation.
- Analyzed the impact of TSG101 and VPS4A on virion production and CTF abundance and localization.
Main Results:
- HIV-1 Gag and APP processing pathways converge on TSG101 and VPS4A, competing for these vesicular trafficking components.
- VPS4A plays a dual role in regulating virion production and CTF levels, influencing infection.
- Depletion of TSG101 impaired HIV-1 Gag localization to MVBs and virion maturation, an effect partially rescued by APP codepletion.
Conclusions:
- HIV-1 Gag and APP processing pathways intersect at TSG101 and VPS4A, creating a competitive interaction that negatively affects HIV-1 replication in microglia.
- The findings reveal a novel mechanism of viral interference involving host cell protein processing pathways.
More Related Videos
14:23A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses
Published on: August 31, 2014
07:10Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
Published on: September 14, 2014